## ITW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

KARIN Nathan et al

Serial No.:

10/749,515

Filed:

January 2, 2004


For:

COMPOSITIONS AND METHODS FOR TREAT

T-CELL MEDIATED AUTOIMMUNE DISEASES

Examiner:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450



Group Art Unit: 1632

Attorney

§ § Docket: 27363

## INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Registration No. 25,457

Dated: November 18, 2004

Approved for use through 07/31/2006. OMB 0651-003 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMER

Index the Panerwork Reduction Act of 1995, no persons are required \$155 table and property Reduction Act of 1995, no persons are required \$155 table and property of information unless it contains a valid OMR control number.


Substitute for form 1440A/PTO						Complete if Known							
Substitute for form 1449A/PTO						tion Number	1	10/749,515					
INFORMATION DISCLOSURE						ate	J.	January 2, 2004					
STATEMENT BY APPLICANT						med Inventor	K	KARIN Nathan et al					
	6	use as many sheets as nec	(crapso		Art Unit		1	632					
						er Name							
Sheet		1	of	2		y Docket Numb	er 2	7363					
U.S. PATENT DOCUMENTS  Examiner   Cite   Document Number   Publication Date   Name of Patentee or   Pages, Columns, Lines, Where													
Examiner Initials*	Cite No. 1	Document Number		D-YYYY	A	Name of Patentee or Applicant of Cited Documen		Relevant Passages or F					
		Number-Kind Code <sup>2 (if known)</sup>								_			
	1	5,985,863	11-16-1999			Su et al.							
<del>-</del>									<del></del>				
										_			
										_			
						·							
				•									
				<del>.</del>						_			
			-										
				-									
			FOREI	GN PAT	ENT DOC	UMENTS							
Examiner Initials*	Cite No. 1	Foreign Patent Documents  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)  PCT 97/24441		Pub	lication Date	D-YYYY Applicant of Cited Document			Pages, Columns, Lines,	т			
	1.0.			— мм	-DD-YYYY				Where Relevant Passages Relevant Figures Appear	T 6			
	2				0-1997					$\vdash$			
	3	PCT 98/41232			4-1998		Sekut et al.			П			
	4	PCT 91/09967		07-1	1-1991	Adair et al.				П			
Examiner						Date							
Signature	•						Considere	d					

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE formation unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to

	Su	bstitute for form 1449A/PTO		Complete if Known					
		0 D J F   MY 0 J   D J 0 G V	_	Application Number	10/749,515				
	INF	ORMATION DISCLOSUR	${f E}$	Filing Date	January 2, 2004				
	STA	TEMENT BY APPLICAN	Τ	First Named Inventor	KARIN Nathan et				
				Group Art Unit	1632				
	_	(use as many sheets as necessary)		Examiner Name					
Sheet	2	Of	2	Attorney Docket Number	27363				
		OTHER PRIOR ART – NON							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	5	Konishi K. et al "A Simple and Sensitive Bioassay for the Detection of Human Interleukin-18/Interferon-y-Inducing Factor Using Human Myelomonocytic KG-1 Cells", Journal of Immunological Methods 209(2): 187-191, 1997.							
	6	Wildbaum Gizi et al. "Adminsitration of Anti-Iterferon Gamma Inducing Factor (IGIF) Antibodies Shifts the Th1/Th2 Balance Towards IL-4 Producing Th2 Cells and Prevents Experimental Autoimmune Encephalomyelitis", Journal of Autoimmunity: 118, 1999.							
	7	Wildbaum, Gizi et al. "Neutralizing Antibodies to IFN-gamma-Inducing Factor Prevent Experimental Autoimmune Encephalomeylitis", The Journal of Immunology 161(11), 1998.							
	8	Okamura et al. "Cloning of a New Cytokine that Induces IFN-y Production by T Cells", Nature 378: 88-91, 1995.							
	9	Taniguchi, M. et al. "Characterization of Anti-Human Interleukin-18 (IL-18)/Interferon-y-Inducing Factor (IGIF) Monoclonal Antibodies and their Applocation in the Measurement of Human IL-18 by ELISA", Journal of Immunological Methods 206: 107-113, 1997.							
	10	Revoltella "Natural and Therapeutic Biotherapy 10(4): 321-331, 1998.		odies to Cytokines",					
	11	Kim et al. "Modulation of Amplitude and Direction of in vivo Immune Responses by Co-Administration of Cytokine Gene Expression Cassettes with DNA Immunogens", Eur. J. Immunol 28: 1089-1103, 1998.							
	+	1							

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Signature

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant's unique citation designation number (optional).

3. Applicant's unique citation designation number (optional).

4. Applicant's unique citation designation number (optional).

5. Applicant's unique citation designation number (optional).

6. Applicant's unique citation designation number (optional).

7. Applicant's unique citation designation number (optional).

7. Applicant's unique citation designation is attached.

7. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of the completed application form to the USPTO. Time will vary depending upon the individual case. of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Considered